for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-GNI Group gets IND clearance by FDA for liver fibrosis treatment

Oct 9 (Reuters) - GNI Group Ltd

* GNI Group announces clearance of investigational new drug (IND) by FDA for F351 clinical trials in the treatment of liver fibrosis

* GNI Group ltd does not expect submission will impact financial results for year ending December 31, 2017

* GNI USA intends to initiate necessary procedures to start a phase I open label study in U.S. in early 2018

* Preliminary results are expected within 2018 Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up